67.91 0.00 (0.00%)
After hours: 5:07PM EDT
|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||67.26 - 69.11|
|52 Week Range||36.23 - 81.91|
|Beta (3Y Monthly)||0.07|
|PE Ratio (TTM)||14.18|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Accenture's (ACN) Health & Public Services and Products segments are likely to get a boost with the inclusion of Ella and Ethan in its Intelligent Patient Platform.
Interpublic's (IPG) digital capabilities, diversified business model and geographic reach offer a distinctive competitive advantage.
Booz Allen (BAH) is currently in the process of implementing Vision 2020, a strategy aimed at achieving sustainable long-term growth.
Mid-caps stocks, like FTI Consulting Inc (NYSE:FCN) with a market capitalization of US$2.85b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
FTI Consulting's (FCN) international operation should help expand its geographic footprint and contribute to top-line growth.
Moody's Investors Service ("Moody's") upgraded FTI Consulting, Inc.'s ("FTI Consulting") Corporate Family Rating (CFR) to Ba1 from Ba2 and its Probability of Default Rating (PDR) to Ba1-PD from Ba2-PD. Moody's also upgraded the company's 6% senior unsecured notes due 2022 to Ba2 from Ba3 and affirmed its Speculative Grade Liquidity (SGL) rating at SGL-1. The ratings outlook is stable.
Zacks.com highlights: Medifast, Endo International, HCA Healthcare, Five9 and FTI Consulting